But like everything else, we should not rush to conclusions
AOD 9604 is not associated with any adverse side effects
The SURPASS clinical trial program demonstrated that tirzepatide at its highest dose (15 mg weekly) produced average weight loss of 20-25% of body weight, significantly exceeding the results seen with GLP-1 only agonists
In this blog, we will cover what MOTS-c is, how it works, what benefits science currently backs, common dosing practices, and its safety profile
Anti-inflammatory effects reduce swelling within the tunnel, decreasing pressure on the nerve
This makes it good for injury modeling, recovery timing studies, and tissue resilience testing